Sl. No.	Disp./Unit	Doctor	
		Male	Female
6.	Tilak Nagar Unit	—	2
7.	Kali Bari Dispy.	1	1
8.	South Avenue Unit	1	1
9.	R.K. Puram, Sector-XII Dispy.	—	3
10.	R.K. Puram, Sector-III Unit	—	2
11.	Kasturba Nagar Unit	1	1
12.	Kalkaji Unit	1	1
13.	Pushp Vihar Unit	—	2
14.	Homoeo Store Depot	1	—
15.	M.O., CGHS Wing, Safdarjung Hospital	1	—

(b) to (d) There is no fixed ratio of posting of male/female doctors in CGHS homoeopathic dispensaries/units. These posts are filled through the UPSC and as and when the UPSC nominates the selected candidates, the posting of doctors is made as per their availability irrespective of whether they are male/female doctors.

Supply of South Korean Encephalitis vaccine in Andhra Pradesh

2711. DR. C. NARAYANA REDDY: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that Japanese Encephalitis vaccine is not available to the extent of the requirement in Andhra Pradesh;

(b) whether it is also a fact that scarcity of South Korean variety of vaccine is affecting Japanese Encephalitis control measures; and

(c) if so, whether Government would take immediate measures to ensure supply of adequate quantity of South Korean variety of Encephalitis vaccine?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI A. RAJA): (a) to (c) Central Research Institute,

Kasauli which is the only manufacturer of JE vaccine in the country manufactures about 2 lakhs doses of the mouse brain vaccine annually for JE control. Since this quantity is not sufficient to meet the requirement of Andhra Pradesh, the State Govt. has been permitted to import inactivated mouse brain JE vaccine after obtaining clearance from the Drugs Controller General of India.

News-item "Government dithers on lifeline for cancer patients"

2712. SHRI KARNENDU BHATTACHARJEE: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether Government's attention has been drawn to the news-item captioned, "Government dithers on lifeline for cancer patients", which appeared in the 'Times of India' dated 19th July, 2002;

(b) if so, Government's reaction thereto; and

(c) the difficulties of Government to give a certificate as required by the pharmaceutical company although a similar certificate was furnished on the last occasion also under a similar situation?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI A. RAJA): (a) to (c) Yes, Sir. Thalidomide is well-known to cause severe birth defects and because of this, the drug was banned all over the world. However, based on the evidence and study reports, USFDA allowed the drug Thalidomide for treatment of leprosy complications for which no good alternative therapies are available for such patients. Thalidomide has also been found useful in the treatment of refractory cases of multiple myeloma. Dr. J.K.Grover, Additional Professor, Pharmacology, AIIMS, New Delhi had conducted trial on patients of multiple myeloma, for which Thalidomide tablets were supplied by M/s Grunenthal, Germany. M/s Grunenthal, Germany, subsequently discontinued the supply of the drug seeking an undertaking from the Government in the form of an agreement. The firm has now agreed to resume the supply of the drug through Central Leprosy Training and Research Institute, Chingelpet as per previous agreement.